Drugs / R906289
R906289
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05308264 | Sep 2022 → Aug 2026 overdue | myelodysplastic syndrome | Rigel Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | R906289 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05308264 ↗ |
| Known as | R289 Na | “Drug: R906289 Monosodium (R289 Na) R906289 Monosodium (250mg PO qd, 250mg PO bid, 500 mg PO qd, 500 mg PO bid, 750 mg PO qd, split dose - 500 mg PO AM/250 mg PO PM)” NCT05308264 ↗ |
| Known as | R906289 Monosodium | “Drug: R906289 Monosodium (R289 Na) R906289 Monosodium (250mg PO qd, 250mg PO bid, 500 mg PO qd, 500 mg PO bid, 750 mg PO qd, split dose - 500 mg PO AM/250 mg PO PM)” NCT05308264 ↗ |